Gordon Phillips to Myeloablative Agonists
This is a "connection" page, showing publications Gordon Phillips has written about Myeloablative Agonists.
Connection Strength
0.230
-
Chaudhry HM, Bruce AJ, Wolf RC, Litzow MR, Hogan WJ, Patnaik MS, Kremers WK, Phillips GL, Hashmi SK. The Incidence and Severity of Oral Mucositis among Allogeneic Hematopoietic Stem Cell Transplantation Patients: A Systematic Review. Biol Blood Marrow Transplant. 2016 Apr; 22(4):605-616.
Score: 0.118
-
Phillips GL. Allogeneic hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS): how can we improve outcomes in the near future? Leuk Res. 2012 Dec; 36(12):1490-5.
Score: 0.095
-
Lazarus HM, Phillips GL, Herzig RH, Hurd DD, Wolff SN, Herzig GP. High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later. J Clin Oncol. 2008 May 10; 26(14):2240-3.
Score: 0.018